inPractice® - Voxilaprevir

Voxilaprevir is an NS3/NS4A protease inhibitor
Voxilaprevir, coformulated with sofosbuvir and velpatasvir, is approved by the FDA for 12-week retreatment of genotypes 1-6 HCV after previous failure of an NS5A inhibitor–containing regimen and genotypes 1a or 3 after previous failure of a sofosbuvir-containing regimen^{[FDA Sofosbuvir Velpatasvir Voxilaprevir]}
- The EMA has approved sofosbuvir/velpatasvir/voxilaprevir for treatment of genotypes 1-6 HCV infection in both DAA-naive and DAA-experienced populations^{[EMA Sofosbuvir Velpatasvir Voxilaprevir]}